Thomas Bergmann serves as Chief Operating Officer (COO) of JG Consulting in Switzerland where he is responsible for all investments, business and operations of a substantial family organization. This includes several corporate merger and acquisition activities as well as public offerings. In this respect he served between 2004 and 2007 as CEO of Macromed, Inc. a private US based pharmaceutical company, which he sold to BTG, PLC (BGC.L), a large publicly traded pharmaceutical company in the United Kingdom. Before this, Mr. Bergmann worked for eleven years at Daimler AG (formerly Daimler-Chrysler) in various sales, IT and senior management positions. As Vice President of Daimler Chrysler Switzerland, he was responsible for business development in Switzerland. Mr. Bergmann is a graduate of the University of Stuttgart in Germany where he received a MBA in Economics and IT Management. Mr. Bergman serves as Chairman of the Board of the BioEqual Group, which develops cosmetical and medical device products, as well as NeuroTell, a CNS development company. Further to this he serves as Board Member of the Swiss subsidiary of Antares Pharma, Inc. (AIS), a publicly traded pharmaceutical company in New Jersey.
Leonard S. Jacob M.D., Ph.D., D.Sc. (Hon) Dr. Jacob received his M.D. from the Medical College of Pa. in 1978 and served on its Board from 1986 to 1998. He currently serves as Chairman of the Board of Antares Pharma. Inc., a publicly traded drug delivery and device company. He also serves on Board of the University of the Sciences and the Temple University School of Medicine. Previously, Dr. Jacob served as worldwide vice president of SmithKline Pharmaceutical Co. and was a member of their Corporate Management Committee. For the past two decades he has been an entrepreneur, co-founding, the Genaera Corp., a publicly traded biotechnology company and InKine Pharmaceuticals a publicly traded gastrointestinal specialty pharmaceutical company. Recently, Dr. Jacob served as Chairman of Bradley Pharmaceuticals.
Dr. Jacob has overseen the development of seven prescribed drugs impacting human health and is the named inventor on six patents. In 2004, Dr. Jacob was given the outstanding alumnus award from the Temple University School of Medicine. In 2008 he was bestowed an honorary doctor of science degree by the University of the Sciences and in early 2010 he was given the “outstanding entrepreneur award” and later that year “the distinguished achievement award in clinical research” from the Drexel University School of Medicine.
Lawrence Jay Kessel, M.D. F.A.C.P. has served on our Board of Directors since November 2006. Since 1984, Dr. Kessel has served as President of Lawrence J. Kessel, M.D. & Associates, PC, a physician practice specializing in internal medicine and geriatrics. He completed a formal residency in Internal Medicine at Abington Memorial Hospital and is Board Certified in Internal Medicine and Geriatric Medicine. He is an active attending staff and clinical instructor at Chestnut Hill Hospital (University of Pennsylvania affiliate) and Roxborough Memorial Hospital in Philadelphia, Pennsylvania. Dr. Kessel previously served on the boards of Cypress Biosciences, Inc., NovaDel Pharma Inc., and Dor BioPharma, Inc. and KERYX inc. He received his B.S. from the University of Pittsburgh and his M.D. from the Temple University School of Medicine. Dr. Kessel is a board reviewer for the American Board of Internal Medicine, and a Fellow of the American College of Physicians. Dr. Kessel served on the advisory board of Independence Blue Cross and is a clinical assistant professor in the department of medicine at Temple University Medical School.